Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383428 | 0.89 | KMT2A (0.63) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2909175 | 0.88 | MAOB (0.60) | MAOBMRGPRX4NR4A2ALOX5 | |
| SCHEMBL20830727 | 0.87 | DHODH (0.57) | POLBKMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL7373666 | 0.87 | ALDH1A1 (0.61) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2326578 | 0.87 | MEN1 (0.61) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2323743 | 0.85 | MEN1 (0.55) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL20831008 | 0.85 | ALDH1A1 (0.49) | POLBKMT2AALDH1A1MRGPRX4TDP1 | |
| SCHEMBL7947250 | 0.84 | TDP1 (0.65) | POLBKMT2AMEN1ALDH1A1MAOB | |
| SCHEMBL20830729 | 0.84 | TDP1 (0.59) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4132618 | 0.83 | ALDH1A1 (0.64) | POLBKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| CN-102369194-A | Novel pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2012-03-07 | — | — | CN | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| CN-101006087-B | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER | 2010-09-29 | — | — | CN | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| US-20090012079-A1 | Triazolopyridine Compounds | LEWTHWAITE RUSSELL ANDREW | 2009-01-08 | — | — | US | disclosed |
| EP-1984363-A1 | TRIAZOLOPYRIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091152-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| CN-101006087-A | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1778686-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018718-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | POLB 2000/4885KMT2A 4210/4885MEN1 4865/4885 |
| US-20090012079-A1 | Triazolopyridine Compounds | MAPKAPK5, MAPK1, MAPK4 | POLB 1883/4885KMT2A 4216/4885MEN1 4823/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | POLB 1393/4885KMT2A 3652/4885MEN1 3585/4885 |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | POLB 1393/4885KMT2A 3652/4885MEN1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.